Abstract
Objective: Low-grade serous ovarian carcinomas (LGSOC) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%–60% of LGSOC. A phase II study of the MEK inhibitor selumetinib showed promising response rate of 15% in LGSOC, and binimetinib, a potent MEK1/2 inhibitor, has demonstrated activity across multiple cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have